文献速递儿童青少年精神

注意缺陷多动障碍及其共病中的可成药基因组:治疗新途径

Druggable genome in attention deficit/hyperactivity disorder and its co-morbid conditions. New avenues for treatment.
PubMed 文献 · Mol Psychiatry · 2019-10-18

该研究利用注意缺陷多动障碍(ADHD)及其共病的全基因组关联研究探索可成药基因组,发现当前一线ADHD药物靶点基因均未与ADHD显著关联,而1、4、12号染色体三个位点含九个可成药基因,提示信号转导与细胞黏附是潜在新治疗方向。

要点

  • 当前ADHD一线药物靶点基因均未与ADHD显著关联,提示其可能通过不同机制起效。
  • 1、4、12号染色体三个位点与ADHD显著关联,含九个可成药基因。
  • 信号转导与细胞黏附被列为ADHD潜在新治疗途径。

核心结论

  • 当前ADHD一线药物靶点基因均未与ADHD显著关联,FDA批准的ADHD药物可能通过不同于ADHD病因的机制起效。
  • 1、4、12号染色体三个位点与ADHD显著关联,含九个可成药基因,其中五个编码恶性肿瘤、自身免疫和神经发育障碍的已有药物靶点。
  • 信号转导与细胞黏附是ADHD潜在的新治疗途径。

研究设计与样本

  • 利用ADHD及其共病的全基因组关联研究探索可成药基因组。
  • 首先检验当前ADHD药物靶点基因与ADHD及其共病的关联,再识别可被药理 agent 靶向的ADHD相关基因与通路。

主要发现

  • 当前ADHD一线药物靶点基因均未与ADHD显著关联。
  • 1、4、12号染色体三个位点与ADHD显著关联,含九个可成药基因。
  • 九个可成药基因中五个编码恶性肿瘤、自身免疫和神经发育障碍的已有药物靶点。

临床怎么用

  • 提示ADHD药物治疗可能不直接针对疾病病因,需探索信号转导与细胞黏附等新靶点。
  • 可成药基因组分析框架可用于评估其他精神障碍的候选药物靶点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Attention-Deficit/Hyperactivity Disorder (ADHD) is a common neurodevelopmental disorder with only symptomatic care available. Genome-wide association (GWA) studies can provide a starting point in the search for novel drug targets and possibilities of drug repurposing. Here, we explored the druggable genome in ADHD by utilising GWA studies on ADHD and its co-morbid conditions. First, we explored whether the genes targeted by current ADHD drugs show association with the disorder and/or its co-morbidities. Second, we aimed to identify genes and pathways involved in the biological processes underlying ADHD that can be targeted by pharmacological agents. These ADHD-associated druggable genes and pathways were also examined in co-morbidities of ADHD, as commonalities in their aetiology and management may lead to novel pharmacological insights. Strikingly, none of the genes encoding targets of first-line pharmacotherapeutics for ADHD were significantly associated with the disorder, suggesting that FDA-approved ADHD drugs may act through different mechanisms than those underlying ADHD. In the examined druggable genome, three loci on chromosomes 1, 4 and 12 revealed significant association with ADHD and contained nine druggable genes, five of which encode established drug targets for malignancies, autoimmune and neurodevelopmental disorders. To conclude, we present a framework to assess the druggable genome in a disorder, exemplified by ADHD. We highlight signal transduction and cell adhesion as potential novel avenues for ADHD treatment. Our findings add to knowledge on known ADHD drugs and present the exploration of druggable genome associated with ADHD, which may offer interventions at the aetiological level of the disorder.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Hegvik TA, Waløen K, Pandey SK, et al. Druggable genome in attention deficit/hyperactivity disorder and its co-morbid conditions. New avenues for treatment. Mol Psychiatry. 2019. PMID: 31628418. doi:10.1038/s41380-019-0540-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。